What Dextra Laboratories does

Dextra Laboratories is a Reading, UK-based specialist in carbohydrate chemistry founded in 1989 and operating as part of the ICE Pharma group. The company operates two business lines: a catalogue of carbohydrate research products and a contract development and manufacturing (CDMO) service offering spanning the development lifecycle. Its catalogue covers blood group antigens, glycoconjugates (including neoglycoproteins and neoglycolipids), oligosaccharides (including human milk oligosaccharides, N-glycans, and tumour antigens), monosaccharides, nucleosides and nucleotides, and polysaccharides, sold through a direct e-commerce storefront and a four-region distributor network covering Japan (Funakoshi), Germany (MoBiTec), China (Adhoc International), and the USA (Amerigo Scientific).

The CDMO service offering is structured as six integrated modules: discovery chemistry (milligram-to-gram parallel synthesis with automated purification), route scouting (evaluating safety, raw material availability, economics, waste, and IP), process development (optimization, scale-up, impurity tracking via NMR/HPLC), non-GMP tox batches at multi-kilogram scale for IND-enabling studies, cGMP manufacturing in two ISO-8 cleanrooms with reactors up to 50L operating from -90°C to +200°C for Phase 1/2 clinical trial material, and comprehensive analytical services (HPLC, UHPLC, NMR, FTIR, GC, mass spectrometry, Karl Fischer, stability studies). Proprietary technology includes neoglycoprotein synthesis with MALDI-TOF analysis for quantifying carbohydrate residues per carrier protein.

Revenue is generated through three streams: catalogue product sales (one-time unit purchases priced in GBP/EUR/USD), custom synthesis services (quote-based, project-based engagements from milligrams to multi-kilogram), and analytical testing services (published price list with set-up and per-sample rates, tiered by Non-GMP vs GMP). Customers are primarily pharmaceutical and biotechnology companies requiring carbohydrate intermediates, GMP APIs, and clinical trial material, with secondary segments in academic/research institutions and life science research organizations. The company holds ISO9001:2015 certification and has sponsored the RSC Dextra Carbohydrate Chemistry Award since 1970.

Name

Dextra Laboratories

Legal name

Dextra Laboratories

Website

https://dextrauk.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

Dextra Laboratories is a Reading, UK-based carbohydrate chemistry specialist (founded 1989, ICE Pharma group) providing a catalogue of blood group antigens, oligosaccharides, glycoconjugates, and related reagents alongside integrated CDMO services from discovery chemistry through cGMP manufacturing for Phase 1/2 clinical trials, serving pharmaceutical, biotech, academic, and life science customers.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (Carbohydrate Chemistry CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

akta.pro secondary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Carbohydrate synthesis
• Glycoconjugate chemistry
• Pharmaceutical contract manufacturing
• GMP manufacturing services
• Analytical testing services

Headquarters

HQ city

Reading

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Catalogue Product Sales: Sale of standardized carbohydrate products from catalogue including blood group products, glycoconjugates, oligosaccharides, monosaccharides, nucleosides, nucleotides, and polysaccharides. Products sold in various pack sizes with unit pricing.
2. Custom Synthesis Services: Bespoke carbohydrate synthesis services from discovery chemistry through route scouting, process development, tox batches, and GMP manufacturing. Services are tailored to client requirements from milligram to multi-kilogram scale.
3. Analytical Testing Services: Contract laboratory analytical services including QC release testing, impurity profiling, method development and validation, stability studies, and cleaning verification. Pricing based on analysis type (Non-GMP vs GMP) with set-up and per-sample rates.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels4 records

Core offering

Dextra Laboratories is a specialist contract developer and manufacturer of carbohydrate-based compounds, supplying both a catalogue of carbohydrate chemistry products (blood group antigens, glycoconjugates, oligosaccharides, monosaccharides, nucleosides, nucleotides, and polysaccharides) and bespoke services spanning discovery chemistry, route scouting, process development, tox batches, cGMP manufacturing for Phase 1/2 clinical trials, and contract analytical testing. The company serves pharmaceutical, biotechnology, life science and academic customers from its Reading, UK facility.

Product overview

Dextra Laboratories is a carbohydrate synthesis specialist providing both a comprehensive catalogue of carbohydrate products and integrated CDMO (Contract Development and Manufacturing Organisation) services. The product portfolio comprises six core product categories: Blood Group Products (antigens and oligosaccharides), Glycoconjugates (neoglycoproteins, neoglycolipids, biotinylated compounds), Oligosaccharides (including glycans, HMOs, tumour antigens), Monosaccharides (building blocks and rare sugars), Nucleosides & Nucleotides, and Polysaccharides. These are complemented by a suite of six service modules forming an end-to-end offering from discovery chemistry through to GMP manufacturing for clinical trials, including route scouting, process development, tox batches, and comprehensive analytical services. The company operates from Reading, UK and is part of ICE Pharma group.

Differentiator

Problem solved

Functional benefit

Brands

• AFFINIDEX: Affinity column product line featuring carbohydrate-conjugated Sepharose columns for research applications
• Custom Neoglycoprotein Service

Products and services

• Blood Group Products

Quantifiable outcome

• Frequent reduction in synthetic steps through alternative route scouting
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Royal Society of ChemistrycoreStrategic or Co-development Partner · 1 January 1970Long-standing sponsorship partnership for the RSC Dextra Carbohydrate Chemistry Award, established in 1970. The award recognizes excellence in carbohydrate chemistry and is presented at RSC Carbohydrate Group meetings. Previous winners include Nobel Laureate Sir Fraser Stoddart.
• ICE PharmacoreStrategic or Co-development PartnerICE Pharma is the parent company of Dextra Laboratories. Founded more than 60 years ago, ICE Pharma is a global niche API and speciality ingredient manufacturer and one of the main global players in bile-related products, with a network of specialist facilities and subsidiaries in Europe, Asia, Oceania, North and South America. Through this partnership, Dextra provides leading expertise in carbohydrate synthesis, analysis and manufacture to the group.
• FunakoshicoreChannel Partner/ Reseller/ DistributorJapanese distributor supplying the full range of Dextra products. Located in Tokyo, Japan. Products available through their website and catalogues.
• MoBiTeccoreChannel Partner/ Reseller/ DistributorGerman distributor (MoBiTec GmbH, Göttingen) supplying the full range of Dextra glycobiology products since 1987.
• Adhoc InternationalcoreChannel Partner/ Reseller/ DistributorChinese distributor serving pharmaceutical, fermentation and coating industries. Located in Beijing, China.
• Amerigo ScientificcoreChannel Partner/ Reseller/ DistributorUS distributor focused on providing critical products and services to the biomedical and life science research communities. Located in Hauppauge, NY.
• Professor Bruno Linclau (Ghent University)minorStrategic or Co-development PartnerAcademic collaborator specializing in fluorination of organic compounds and its applications in drug discovery. Dr. Linclau joined Ghent University as Odysseus Research Professor in 2021 after being Professor at Southampton University.
• Professor Kim Watson (University of Reading)minorStrategic or Co-development PartnerAcademic collaborator specializing in structural biochemistry and carbohydrate binding proteins. Fellow of Royal Society of Biology, Royal Society of Chemistry, and Higher Education Academy. Secured over £4M research funding in last 5 years.
• Professor Helen Osborn (University of Reading)minorStrategic or Co-development PartnerAcademic collaborator specializing in biomedicinal chemistry with research in enzyme activated prodrugs, carbohydrate biomarkers, and polymer drug conjugates. Professor of Biomedicinal Chemistry and Deputy Head of School.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Biosynth (Carbosynth): Biosynth's Carbosynth division is a UK-rooted specialist in carbohydrate chemistry and rare sugars, selling a catalogue of oligosaccharides, monosaccharides, and glycoconjugates alongside custom synthesis. Directly comparable in product portfolio, chemistry niche, and catalogue-plus-custom business model.
• Sussex Research: Specialty carbohydrate chemistry services company offering custom synthesis, neoglycolipids, and oligosaccharide tools. Highly comparable to Dextra in scale, customer base (glycobiology researchers and pharma), and chemistry specialization.
• IsoSciences: US-based specialty chemistry company focused on labeled and unlabeled carbohydrates, nucleosides, and stable isotope compounds with custom synthesis services. Directly comparable in chemistry niche and target customer profile.
• Toronto Research Chemicals: Canada-based specialty manufacturer of catalogue reference standards, impurities, and complex organic compounds including carbohydrates and nucleosides. Comparable as a catalogue-and-custom specialty chemistry supplier to research and pharma customers.
• TCI Chemicals: Japan-headquartered catalogue chemicals supplier with extensive carbohydrate, nucleoside, and rare sugar listings plus custom synthesis. Comparable in catalogue breadth, multi-region distribution, and academic/pharma customer overlap.

Broad incumbents

• Bachem: Large Swiss CDMO specializing in peptides and oligonucleotides with GMP manufacturing for clinical and commercial supply. Overlaps with Dextra in complex-chemistry CDMO and GMP capabilities but at vastly larger scale and broader modality.
• Carbogen Amcis: Swiss-headquartered CDMO offering API development and GMP manufacturing, including complex small molecules and carbohydrates. Comparable as a CDMO serving pharma with GMP capacity, though broader in modality.
• Asymchem: Large China-based CDMO providing custom synthesis, process development, and GMP manufacturing for innovative APIs. Comparable as a CDMO serving global pharma with regulated manufacturing, though at far greater scale and modality breadth.
• WuXi STA (WuXi AppTec): Major global CDMO with API development and GMP manufacturing capacity across small molecules, oligonucleotides, and peptides. Comparable in end-to-end CDMO service model but vastly larger scale and broader modality coverage.
• SAI Life Sciences: India-headquartered CDMO providing drug discovery, process chemistry, and GMP manufacturing services. Comparable as a discovery-to-GMP CDMO serving global pharma, though with broader therapeutic-area focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dextrauk

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dextra Laboratories